Form 4: Precigen CFO Sells Shares Under 10b5-1 Plan

Precigen, Inc. CFO Harry Thomasian Jr. reported the sale of company stock under a pre-arranged trading plan.

Summary

• Harry Thomasian Jr., Chief Financial Officer of Precigen, Inc., has reported transactions involving the sale of common stock.
• These sales occurred on June 29, 2026, and July 1, 2026.
• The transactions were conducted under a Rule 10b5-1 trading plan, which is designed to comply with affirmative defense conditions for insider sales.
• On June 29, 2026, 28,571 shares were sold at a weighted average price of $5.78.
• On July 1, 2026, 171,429 shares were sold at a weighted average price of $5.53.
• Following these transactions, Thomasian beneficially owns 354,535 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative sentiment due to the significant sale of shares by the CFO, even though it was executed under a pre-arranged 10b5-1 plan.

Negatives

• The Chief Financial Officer has sold a significant number of shares (200,000 shares in total across two transactions).
• The sales represent a reduction in direct beneficial ownership by a key executive.

Risks

• The sale of a substantial number of shares by a key executive could be interpreted negatively by the market, potentially impacting investor sentiment.
• While conducted under a 10b5-1 plan, the timing of the sales relative to any company news or performance could still raise questions.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports past transactions.

Management Comments

• The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
• The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

Industry Context

StockSavvy.ai notes that Form 4 filings reporting insider sales under 10b5-1 plans are common. While these plans are designed to avoid insider trading concerns, significant sales by executives can still influence market perception, especially if they occur during periods of company volatility or before major announcements.

Stakeholder Impact

• Shareholders may view the CFO's sale of a substantial number of shares with concern, potentially leading to short-term negative pressure on the stock price.
• Employees with stock options or grants may be influenced by the executive's decision to sell, though the 10b5-1 plan mitigates insider trading concerns.

Next Steps

• The reporting person has undertaken to provide detailed pricing information upon request from the SEC, issuer, or security holders.

Key Dates

Recommendation

The filing reports insider sales under a 10b5-1 plan, which is a standard procedure. While the sale of a significant number of shares by the CFO could be a short-term negative signal, the execution via a pre-arranged plan suggests it's not necessarily a reflection of negative non-public information about the company's future prospects. Therefore, a 'hold' recommendation is appropriate pending further company-specific developments.

Keywords

Precigen, PGEN, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, CFO, Securities Exchange Act, Beneficial Ownership